258 filings
Page 7 of 13
8-K
29wjwpgqocimc
8 Jan 18
Regulation FD Disclosure
12:00am
8-K
dz220pt9f73cv 9zm
3 Jan 18
Departure of Directors or Certain Officers
12:00am
8-K
zz2s9sc e0e
18 Dec 17
Other Events
12:00am
CT ORDER
l06ovt gcob
28 Nov 17
Confidential treatment order
12:00am
8-K
wxo32xhggwfpj9qrso3
15 Nov 17
Departure of Directors or Certain Officers
12:00am
8-K
hzms502wqtqusw3dkx
7 Nov 17
Acceleron Pharma Reports Third Quarter 2017 Operational and Financial Results
12:00am
8-K
zb16u67dlv4y9id
25 Sep 17
Other Events
12:00am
424B2
wm3h xmg7f
21 Sep 17
Prospectus for primary offering
12:00am
S-3ASR
xbrgh25x0lq
19 Sep 17
Automatic shelf registration
12:00am
8-K
jjtmp9
19 Sep 17
Entry into a Material Definitive Agreement
12:00am
424B5
qrt06pqaawi5iavh
19 Sep 17
Prospectus supplement for primary offering
12:00am
8-K
0e0sl6 j2dpog3
3 Aug 17
Acceleron Pharma Reports Second Quarter 2017 Operational and Financial Results
12:00am
S-8
vwm3 jxf8kewvj0mlzj
3 Aug 17
Registration of securities for employees
12:00am
8-K
gpa67al m2q4y02ge4hu
19 Jul 17
Entry into a Material Definitive Agreement
12:00am
8-K
u0mh9a7jl 9nn0fz4
30 Jun 17
Other Events
12:00am
8-K
pylc7ckfdh4fphd
15 Jun 17
Acceleron Announces Top-Line Results from DART Phase 2 Study of Dalantercept in Advanced Renal Cell Carcinoma
12:00am
8-K
yzirhw1 eom
6 Jun 17
Submission of Matters to a Vote of Security Holders
12:00am
8-K
wylxn
10 May 17
Luspatercept Phase 2 Data Presented at the 14th International Symposium on Myelodysplastic Syndromes
12:00am